Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

MicroRNAs as Novel Biomarkers for the Diagnosis of Alzheimer's Disease and Modern Advancements in the Treatment

  • Gunasekaran, Tamil Iniyan (Department of Cellular and Molecular Medicine, College of Medicine, Chosun University) ;
  • Ohn, Takbum (Department of Cellular and Molecular Medicine, College of Medicine, Chosun University)
  • Received : 2015.03.24
  • Accepted : 2015.03.30
  • Published : 2015.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Alzheimer's disease is a common form of dementia occurring among the elderly population and can be identified by symptoms such as cognition impairments, memory loss and neuronal dysfunction. Alzheimer's disease was found to be caused by the deposition of $\beta$-amyloid plaques and neurofibrillary tangles. In addition, mutation in the APP (Amyloid precursor protein), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) genes were also found to contribute to Alzheimer's disease. Since the potential conformational diagnosis of Alzheimer's disease requires histopathological tests on brain through autopsy, potential early diagnosis still remains challenging. In recent years, several researches have proposed the use of biomarkers for early diagnosis. In cerebrospinal fluid (CSF), $\beta$-amyloid(1-42), phosphorylated-tau and total tau were suggested to be effective biomarkers for Alzheimer's disease diagnosis. However, a single biomarker might not be sufficient for potential diagnosis of Alzheimer's disease. Thus, the use of RNA interference (RNAi) through microRNAs (miRNAs) has been proposed by several researchers for simultaneous analysis of several biomarkers using microarray technology. These miRNA based biomarkers can be analysed from both blood and CSF, but miRNAs from blood are advantageous over CSF as they are non-invasive and simple for collection. Moreover, the RNAi based therapeutics by siRNA (short interference RNA) or shRNA (short hairpin RNA) have also been proposed to be effective in the treatment of Alzheimer's disease. This review describes the promising application of RNAi technology in therapeutics and as a biomarker for both Alzheimer's disease diagnosis and treatment.

Keywords

References

  1. Barber RC. The Genetics of Alzheimer's Disease. Scientifica. 2012. 2012: 14.
  2. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011. 10: 819-828. https://doi.org/10.1016/S1474-4422(11)70072-2
  3. Bossuyt P. Clinical validity: defining biomarker performance. Scand J Clin Lab Invest Suppl. 2010. 242: 46-52.
  4. Brion J. Neurofibrillary tangles and Alzheimer's disease. Eur Neurol. 1998. 40: 130-140. https://doi.org/10.1159/000007969
  5. Cheng L, Quek C, Sun X, Bellingham SA, Hill AF. Deepsequencing of microRNA associated with Alzheimer's disease in biological fluids: From biomarker discovery to diagnostic practice. Fron Genet. 2013. 4: 150.
  6. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008. 14: 27-41. https://doi.org/10.3233/JAD-2008-14103
  7. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012. 110: 483-495. https://doi.org/10.1161/CIRCRESAHA.111.247452
  8. Crowther RA. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci USA. 1991. 88: 2288-2292. https://doi.org/10.1073/pnas.88.6.2288
  9. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, Ziemann M, Helbing T, El-Osta A, Jowett JBM, Peter K. Microparticles:major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012. 93: 633-644. https://doi.org/10.1093/cvr/cvs007
  10. Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener. 2012. 1: 18. https://doi.org/10.1186/2047-9158-1-18
  11. Du L, Pertsemlidis A. Cancer and neurodegenerative disorders:pathogenic convergence through microRNA regulation. J Mol Cell Biol. 2011. 3: 176-180. https://doi.org/10.1093/jmcb/mjq058
  12. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2012. 6: 455-476. https://doi.org/10.2217/bmm.12.42
  13. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci. 2004. 22: 453-465. https://doi.org/10.1016/j.ijdevneu.2004.07.013
  14. Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013. 73: 729-740. https://doi.org/10.1002/ana.23880
  15. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. 2013. 9: 513-521. https://doi.org/10.1038/nrendo.2013.86
  16. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging. 2012. 33: 437-456. https://doi.org/10.1016/j.neurobiolaging.2010.03.025
  17. Hodges JR. Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain. 2006. 129: 2811-2822. https://doi.org/10.1093/brain/awl275
  18. Hong-Qi Y, Zhi-Kun S, Sheng-Di C. Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Abeta and tau. Transl Neurodegener. 2012. 1: 21. https://doi.org/10.1186/2047-9158-1-21
  19. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 2011. 29: 26-32. https://doi.org/10.1016/j.tibtech.2010.09.007
  20. Hutton M. The presenilins and Alzheimer's disease. Hum Mol Genet. 1997. 6: 1639-1646. https://doi.org/10.1093/hmg/6.10.1639
  21. Jackson-Siegal J. Our current understanding of the pathophysiology of Alzheimer's disease advanced studies in pharmacy. Adv Stud Pharm. 2005. 2: 126-135.
  22. Koutsilieri E, Rethwilm A, Scheller C. The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders. J Neural Transm Suppl. 2007. 72: 43-49. https://doi.org/10.1007/978-3-211-73574-9_7
  23. Kumar P, Dezso Z, MacKenzie C, Oestreicher J, Agoulnik S, Byrne M, Bernier F, Yanagimachi M, Aoshima K, Oda Y. Circulating miRNA biomarkers for Alzheimer's disease. PLoS One. 2013. 8: e69807. https://doi.org/10.1371/journal.pone.0069807
  24. Lukiw W. NF-kappaB-regulated, proinflammatory miRNAs in Alzheimer's disease. Alzheimers Res Ther. 2012. 4: 47. https://doi.org/10.1186/alzrt150
  25. Mayeux R. Biomarkers: potential uses and limitations. Neurotherapeutics. 2004. 1: 182-188. https://doi.org/10.1602/neurorx.1.2.182
  26. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008. 105: 10513-10518. https://doi.org/10.1073/pnas.0804549105
  27. Mokhtar SH, Bakhuraysah MM, Cram DS, Petratos S. The beta-amyloid protein of Alzheimer's disease: Communication breakdown by modifying the neuronal cytoskeleton. Intern J Alzheimers Dis. 2013. 2013: 15.
  28. Mrak RE, Griffin WST. Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis. 2005. 8: 369-375.
  29. Orlacchio A, Bernardi G, Orlacchio A, Martino S. RNA interference as a tool for Alzheimer's disease therapy. Mini Rev Med Chem. 2007. 7: 1166-1176. https://doi.org/10.2174/138955707782331678
  30. Pasinetti GM. Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. J Neurosci Res. 2001. 65: 471-476. https://doi.org/10.1002/jnr.1176
  31. Ray M, Ruan J, Zhang W. Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases. Genome Biol. 2008. 9: R148. https://doi.org/10.1186/gb-2008-9-10-r148
  32. Reger B. Alzheimer's Disease: A brief history and avenues for current research. J Young Invest. 2002. 6.
  33. Reitz C. Alzheimer's disease and the amyloid cascade hypothesis:A critical review. Intern J Alzheimers Dis. 2012. 2012: 11.
  34. Ricciarelli R, d'Abramo C, Massone S, Marinari UM, Pronzato MA, Tabaton M. Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life. 2004. 56: 349-354. https://doi.org/10.1080/15216540412331286002
  35. Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener. 2013. 8: 20. https://doi.org/10.1186/1750-1326-8-20
  36. Salawu F, Umar J, Olokoba A. Alzheimer's disease: A review of recent developments. Ann Afr Med. 2011. 10: 73-79. https://doi.org/10.4103/1596-3519.82057
  37. Shun C, Xuemei G, Yinghui C, Nan L, Zhenguo L, Weien Y. Advances with RNA interference in Alzheimer's disease research. Drug Des Devel Ther. 2013. 7: 117-125.
  38. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005. 8: 1343-1349. https://doi.org/10.1038/nn1531
  39. Tan L, Yu JT, Tan MS, Liu QY, Wang HF, Zhang W, Jiang T, Tan L. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. J Alzheimers Dis. 2014. 40: 1017-1027. https://doi.org/10.3233/JAD-132144
  40. Tricoli JV, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007. 67: 4553-4555. https://doi.org/10.1158/0008-5472.CAN-07-0563
  41. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res. 2012. 110: 496-507. https://doi.org/10.1161/CIRCRESAHA.111.247916
  42. Wang G, Zhang Y, Chen B, Cheng J. Preliminary studies on Alzheimer's disease using cDNA microarrays. Mech Ageing Dev. 2003. 124: 115-124. https://doi.org/10.1016/S0047-6374(02)00188-4
  43. Whalley LJ. Early-onset Alzheimer's disease in Scotland: environmental and familial factors. Brit J Psychiat. 2001. 178: s53-s59. https://doi.org/10.1192/bjp.178.40.s53
  44. Zilka N, Novak M. The tangled story of Alois Alzheimer. Bratisl Lek Listy. 2006. 107: 343-345.